Racha Savitha, Patel Sapan M, Bou Harfouch Layal T, Berger Olivia, Buresh Megan E
Department of Medicine, Division of Addiction Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States of America.
Department of Medicine, Division of Addiction Medicine, Johns Hopkins School of Medicine, Baltimore, MD, United States of America; Johns Hopkins University, Krieger School of Arts and Sciences, United States of America.
J Subst Use Addict Treat. 2023 May;148:209004. doi: 10.1016/j.josat.2023.209004. Epub 2023 Mar 15.
Current methadone titration guidelines recommend low initial doses (15-40 mg) and slow increases (10-20 mg every 3 to 7 days) to prevent dose accumulation and oversedation until reaching a target therapeutic dose between 60 and 120 mg. These guidelines were created primarily for outpatient settings in the pre-fentanyl era. Methadone initiations are becoming more common in hospitals, but no titration guidelines exist specific to this treatment setting, which has capacity for increased monitoring. Our objective was to assess the safety of rapid inpatient methadone initiation with regard to mortality, overdose, and serious adverse outcomes both in-hospital and postdischarge.
This is a retrospective, observational, cohort study conducted at an urban, academic medical center in the United States. We queried our electronic medical record for hospitalized adults with moderate to severe opioid use disorder admitted between July 1, 2018, and November 30, 2021. Included patients were rapidly initiated on methadone with 30 mg as the initial dose and 10 mg increases daily until reaching 60 mg. The study extracted thirty-day post-discharge opioid overdose and mortality data from the CRISP database.
Twenty-five hospitalized patients received rapid methadone initiation during the study period. The study had no major adverse events including in-hospital or thirty-day post-discharge overdoses or deaths. The study did have two instances of sedation, but neither led to methadone dose holds. There were no instances of QTc prolongation. The study had one patient-directed discharge.
This study demonstrated that a small subset of hospitalized patients tolerated rapid methadone initiation. More rapid titrations can be utilized in a monitored inpatient setting to retain patients in the hospital and allow providers to account for increased tolerance in the fentanyl era. Guidelines should be updated to reflect the capabilities of inpatient settings to safely initiate and rapidly titrate methadone. Further work should determine optimal methadone initiation protocols in the fentanyl era.
当前美沙酮滴定指南建议初始剂量要低(15 - 40毫克)且增加剂量要缓慢(每3至7天增加10 - 20毫克),以防止剂量累积和过度镇静,直至达到60至120毫克的目标治疗剂量。这些指南主要是为芬太尼时代之前的门诊环境制定的。在医院中启动美沙酮治疗越来越普遍,但针对这种具有加强监测能力的治疗环境,尚无具体的滴定指南。我们的目的是评估住院患者快速启动美沙酮治疗在院内及出院后死亡率、过量用药及严重不良结局方面的安全性。
这是一项在美国一家城市学术医疗中心进行的回顾性观察队列研究。我们查询了2018年7月1日至2021年11月30日期间收治的患有中度至重度阿片类药物使用障碍的住院成人的电子病历。纳入的患者以30毫克作为初始剂量快速启动美沙酮治疗,每日增加10毫克,直至达到60毫克。该研究从CRISP数据库中提取出院后30天的阿片类药物过量用药和死亡率数据。
在研究期间,25名住院患者接受了快速美沙酮启动治疗。该研究未发生重大不良事件,包括院内或出院后30天内的过量用药或死亡。该研究确实有两例镇静情况,但均未导致美沙酮剂量暂停。没有QTc延长的情况。该研究有一例患者自行出院。
本研究表明一小部分住院患者能够耐受快速美沙酮启动治疗。在有监测的住院环境中可以采用更快的滴定方法,以使患者留在医院,并让医护人员考虑到芬太尼时代耐受性增加的情况。应更新指南以反映住院环境安全启动和快速滴定美沙酮的能力。进一步的工作应确定芬太尼时代美沙酮启动的最佳方案。